Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

10.1038/nm0603-669

10.1038/362841a0

Presta LG, 1997, Cancer Res, 57, 4593

10.1038/nm0901-987

10.1038/nm988

10.1200/JCO.2003.10.066

10.1056/NEJM200009283431302

10.1097/00000421-198212000-00014

10.1093/jnci/92.3.205

10.1200/JCO.2004.09.046

10.1056/NEJMoa021491

Rothenberg ML, 2001, J Clin Oncol, 19, 3801, 10.1200/JCO.2001.19.18.3801

10.1136/gut.52.4.568

Nissen NN, 1998, Am J Pathol, 152, 1445

Hurwitz H, 2002, Prog Proc Am Soc Clin Oncol, 21, 82

Benson AB, 2003, Prog Proc Am Soc Clin Oncol, 22, 243

Hurwitz H, Fehrenbacher L, Cartwright T, et al. A phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC: efficacy results in arm 3 (5-FU/LV/BV) and other exploratory analyses. Presented at the 94th AACR Annual Meeting, Washington, D.C., July 11–14, 2003. abstract. (Accessed on May 10, 2004, at http://www.aacr.org/1132ag.asp.)